AB Science SA
Gesloten
0.959
Overzicht
Wijziging aandelenprijs
24u
Min
0.923
Max
0.961
Inkomsten | 8.8M 3.6M |
|---|---|
Verkoop | 144K 659K |
Winstmarge | 549.317 |
Werknemers | 36 |
EBITDA | 1.8M -727K |
Marktkapitalisatie | -628K 68M |
|---|---|
Vorige openingsprijs | 0.96 |
Vorige sluitingsprijs | 0.959 |
Technische score
By Trading Central
Vertrouwen
Bearish Evidence
AB Science SA Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
AB Science SA Prognose
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over AB Science SA
AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
